Revenue Growth Drivers

Dexcom’s CGM franchise still has room to expand internationally and across diabetes segments, while Abbott remains the main peer with broader scale and faster global reach.

Recurring sensor replacement creates a durable installed-base flywheel, so revenue can compound as penetration rises, though Medtronic’s diabetes business remains smaller and less focused.

New product cycles and software-enabled ecosystem upgrades can lift average revenue per user over time, but growth depends on sustained adoption versus Abbott’s simpler, lower-cost offering.

High ROIC of 21.6% supports reinvestment into commercialization and R&D, which can extend growth duration, although peers with larger distribution footprints can scale faster.

Market Tailwinds

Rising global diabetes prevalence supports multi-year demand growth, and Dexcom is better positioned than smaller peers to convert that demand into recurring sensor revenue.

Continuous glucose monitoring adoption is still underpenetrated outside the U.S., giving Dexcom a longer runway than mature diabetes device peers with slower category expansion.

Broader reimbursement and clinician acceptance can expand addressable usage over time, while Abbott’s Libre has already captured more mainstream volume in many markets.

The category’s shift from episodic testing to continuous monitoring structurally favors recurring consumables, but the tailwind is shared with Abbott and therefore not exclusive.

Scalability Expansion

Dexcom’s model scales efficiently because each incremental user adds recurring sensor demand without proportional manufacturing complexity, unlike more capital-intensive device peers.

Low capex at 6.9% of revenue indicates expansion can be funded without heavy asset buildup, supporting faster scaling than hardware-heavy medtech businesses.

R&D intensity of 12.2% of revenue suggests continued product iteration is affordable, which can extend the platform, though Abbott’s larger scale may spread costs more efficiently.

Net debt to EBITDA of 0.19x leaves substantial balance-sheet capacity for growth investment, but execution must still match Abbott’s broader commercial infrastructure.

Constraints Limitations

Dexcom’s cash conversion cycle of 153 days signals working-capital drag, which can slow cash compounding relative to peers with leaner inventory and receivables management.

Abbott’s Libre franchise creates a strong competitive ceiling, because lower-cost positioning can limit Dexcom’s share gains in price-sensitive markets.

Growth is still concentrated in diabetes CGM, so long-term expansion depends on deeper penetration rather than broad category diversification like larger diversified medtech peers.

Valuation at 21.1x EV/EBITDA implies the market already discounts meaningful growth, which does not limit operations directly but raises the bar versus peers.

Overall Score

Dexcom has strong long-term growth capacity because recurring CGM demand, international penetration, and efficient reinvestment can compound revenue, but Abbott’s scale and pricing pressure cap upside versus top-tier compounders.

Score Driver: Recurring CGM Expansion